Literature DB >> 7721885

Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms.

P Wang1, P Wu, M I Siegel, R W Egan, M M Billah.   

Abstract

Our previous studies in human monocytes have demonstrated that interleukin (IL)-10 inhibits lipopolysaccharide (LPS)-stimulated production of inflammatory cytokines, IL-1 beta, IL-6, IL-8, and tumor necrosis factor (TNF)-alpha by blocking gene transcription. Using electrophoretic mobility shift assays (EMSA), we now show that, in monocytes stimulated with LPS or TNF alpha, IL-10 inhibits nuclear stimulation of nuclear factor kappa B (NF kappa B), a transcription factor involved in the expression of inflammatory cytokine genes. Several other transcription factors including NF-IL-6, AP-1, AP-2, GR, CREB, Oct-1, and Sp-1 are not affected by IL-10. This selective inhibition by IL-10 of NF kappa B activation occurs rapidly and in a dose-dependent manner and correlates well with IL-10's cytokine synthesis inhibitory activity in terms of both kinetics and dose responsiveness. Furthermore, compounds such as tosylphenylalanyl chloromethyl ketone and pyrrolidinedithiocarbamate that are known to selectively inhibit NF kappa B activation block cytokine gene transcription in LPS-stimulated monocytes. Taken together, these results suggest that inhibition of NF kappa B activation may be an important mechanism for IL-10 suppression of cytokine gene transcription in human monocytes. IL-4, another cytokine that inhibits cytokine mRNA accumulation in monocytes, shows little inhibitory effect on LPS-induced NF kappa B activation. Further examination reveals that, unlike IL-10, IL-4 enhances mRNA degradation and does not suppress cytokine gene transcription. These data indicate that IL-10 and IL-4 inhibit cytokine production by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721885     DOI: 10.1074/jbc.270.16.9558

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  151 in total

1.  Interleukin-10 regulates the tissue factor activity of monocytes in an in vitro model of bacterial endocarditis.

Authors:  M H Veltrop; J A Langermans; J Thompson; M J Bancsi
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 2.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

3.  Monocyte-derived dendritic cells: a potential target for therapy in multiple sclerosis (MS).

Authors:  M E Duddy; G Dickson; S A Hawkins; M A Armstrong
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

4.  Activation of nuclear factor kappaB as a target for anti-inflammatory therapy.

Authors:  S Schreiber
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

Review 5.  Sepsis-induced immunosuppression: from bad to worse.

Authors:  R C Reddy; G H Chen; P K Tekchandani; T J Standiford
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 6.  NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions.

Authors:  Jorge Caamaño; Christopher A Hunter
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

Review 7.  Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).

Authors:  Robert R Brubaker
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

8.  Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.

Authors:  Sean van Diepen; Matthew T Roe; Renato D Lopes; Amanda Stebbins; Stefan James; L Kristin Newby; David J Moliterno; Franz-Josef Neumann; Justin A Ezekowitz; Kenneth W Mahaffey; Judith S Hochman; Christian W Hamm; Paul W Armstrong; Pierre Theroux; Christopher B Granger
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

9.  Nanofiber-expanded human umbilical cord blood-derived CD34+ cell therapy accelerates murine cutaneous wound closure by attenuating pro-inflammatory factors and secreting IL-10.

Authors:  Suman Kanji; Manjusri Das; Reeva Aggarwal; Jingwei Lu; Matthew Joseph; Sujit Basu; Vincent J Pompili; Hiranmoy Das
Journal:  Stem Cell Res       Date:  2013-11-15       Impact factor: 2.020

Review 10.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.